The study examined the progresses of a coronary arterial disease among medical, surgical and PTCA treated groups and compared the long-term results with anti-platelet therapy (trapidil 300mg/day or persantin 75mg+aspyrin 300mg/day) or Ca²⁺ channel blockade (nifedipine 40mg/day) groups. 323 patients with effort angina were studied. These were grouped into Group I (96 patients treated medically), Group 11 (147 patients who underwent CABG) and Group III (84 patients treated with PTCA). Group I was further divided into 3 subgroups; I-B 37 cases who were administered with anti-platelet drug for a long period of time, I-C 21 cases who were administered with Ca²⁺ channel blockade and I-A 38 cases with whom none of the 2 drugs was administered. Group II was likewise divided into 3 subgroups of II-B, anti-platelet administered group, II-C, Ca²⁺ channel blockade administered group and II-A, non-administered group. The observation was conducted in 3 to 60 months (average 12.4 months) after the 1st CAG. Serial CAG were taken in each case. The standard of the progress diagnosis was based on Kramer's criteria. RESULTS & CONCLUSION: 1) Among I-A group patients, progress, non-progress, and regress cases were, 50, 40 and 5%, respectively. 55% of the patients showed progress had the effect within 12 months. The level of progress after this period co-relates to the length of observa-tion period, showing 72% peak in over 2 yrs. Relationship with affected vessels; Progress of the responsible coronary arterial vessel with patients involving single vessel disease showed the highest record. The highest rate was with the cases where the disease progressed to a complete occlusion (type 1). On the other hand, among B and C groups, the rate of progress after 2 yrs remarkably became low (p<0.01). LV function was favorable both with I-B, I-C groups. With II-A group, the rate of progress was high in non-grafted vessels within one to one year and a half period with high ratio of type 1, while with II-B, II-C groups, a difference in progress was observed. Among B group patients progression and regression were 33, and 13% within 12 months. While, among C groups, progression, non-progression, and regression were 35, 44 and 21%. 2) Among Group III, 9 cases or 13% showed recurrence of the initially dilated vessel. Of these, 56% showed a significant progress in initally dilated vessel; however, a good result was observed after the 2nd PTCA. 3) These drugs were considered as preventing the progression of coronary artery disease. It is concluded that for angina pectoris patients, a specific treatment program should be established to prevent the progress of the disease, in addition to a conventional therapeutical program. 4) Synergistic effects of these drugs might be resulted from vascular injury suppression, platelet inhibition, coronary vasodilation, improvement of lipids metabolism as well as improvement of LV performance.